Cargando…

Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature

Osteoarthritis (OA) is a physically and emotionally debilitating disease that predominantly affects the aging adult population. Current pharmacologic treatment options primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated side effects, analgesic limitations,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Robert, Raffa, Robert B, Pergolizzi, Joseph V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346069/ https://www.ncbi.nlm.nih.gov/pubmed/22570559 http://dx.doi.org/10.2147/JPR.S21965

Ejemplares similares

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology
por: Pergolizzi, Joseph V, et al.
Publicado: (2016)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Trends and uptake of new formulations of controlled‐release oxycodone in Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease
por: Coluzzi, Flaminia, et al.
Publicado: (2015)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Meta-analysis of efficacy and safety of sustained release oxycodone hydrochloride rectal administration for moderate to severe pain
por: Hou, Xian Bing, et al.
Publicado: (2022)

A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
por: Nosek, Krzysztof, et al.
Publicado: (2017)

Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study
por: Kawamata, Mikito, et al.
Publicado: (2019)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain
por: Pergolizzi Jr, Joseph V, et al.
Publicado: (2019)

Slow drug delivery decreased total body clearance and altered bioavailability of immediate‐ and controlled‐release oxycodone formulations
por: Li, Yan, et al.
Publicado: (2016)

Prophylaxis of Postoperative Nausea and Vomiting in Adolescent Patients: A Review with Emphasis on Combination of Fixed-Dose Ondansetron and Transdermal Scopolamine
por: Pergolizzi, Joseph V., et al.
Publicado: (2011)

Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system
por: Silverman, Sanford, et al.
Publicado: (2017)

Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study
por: Wang, Wenxian, et al.
Publicado: (2018)

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
por: Olatoke, Oluwadara, et al.
Publicado: (2022)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain
por: Pergolizzi, Joseph V, et al.
Publicado: (2012)

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials
por: Blagden, M, et al.
Publicado: (2014)

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study
por: Feng, Weineng, et al.
Publicado: (2022)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain
por: Hale, Martin E, et al.
Publicado: (2015)

Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study
por: Kawamata, Mikito, et al.
Publicado: (2019)

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective
por: Ferrarese, Fabio, et al.
Publicado: (2008)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
por: Pergolizzi, Joseph V, et al.
Publicado: (2017)

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
por: Guerriero, Fabio, et al.
Publicado: (2016)

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients
por: Lauretti, G R, et al.
Publicado: (2003)

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
por: Ahmedzai, Sam H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6nm2dh252f2pbg134rnk6cm0ll